Will ‘Descovy’ change paradigm in HIH treatment?

‘Gilead,’ an international biopharmaceutical company, is currently working hard.

It has decided to launch ‘Descovy(generic name: emtricitabine/tenofovir alafenamide),’ the first HIV backbone treatment containing a TAF substance, with the health insurance benefit on the 1^st of June only in 10 days of acquiring Korean approval of ‘Vemlidy,’ a TAF-based chronic hepatitis B treatment.

Even more s...